MabVax Therapeutics Holdings, Inc. (MBVX) Posts Quarterly Earnings Results
MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) issued its quarterly earnings results on Tuesday. The company reported ($0.54) earnings per share (EPS) for the quarter, Bloomberg Earnings reports.
Shares of MabVax Therapeutics Holdings (MBVX) traded up $0.01 during midday trading on Thursday, reaching $0.65. 94,403 shares of the company traded hands, compared to its average volume of 242,668. The company has a debt-to-equity ratio of 38.83, a quick ratio of 0.28 and a current ratio of 0.28. MabVax Therapeutics Holdings has a 1-year low of $0.43 and a 1-year high of $4.50.
About MabVax Therapeutics Holdings
MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.
Receive News & Ratings for MabVax Therapeutics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MabVax Therapeutics Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.